-
Eli Lilly Full Year 2025 Financial Report
Eli Lilly
Eli Lilly's 2025 results show a 45% revenue increase to $65.2B, driven by Mounjaro and Zepbound sales. With strong growth in profits and an optimistic 2026 outlook, the company continues to lead in metabolic diseases and oncology treatments.
-
Eli Lilly 2025 H1 Report
Financial statements
Eli Lilly's 2025 H1 revenue surged 41% to $28.29B, driven by tirzepatide sales hitting $14.7B. Mounjaro and Zepbound shine as blockbuster drugs, boosting Lilly's global pharmaceutical ranking.
-
-
-
-
Pharma's $158B U.S. Manufacturing Surge
Market Trend
Major pharmaceutical companies pledge $158 billion to U.S. manufacturing to sidestep tariff threats, funding facilities from California to North Carolina. Lilly, J&J, Novartis, Roche and Regeneron drive billions in reshoring investments, creating thousands of jobs.
-
Stylus Medicine Raises $85 Million!
Eli Lilly
Stylus Medicine raises $85M to develop in vivo CAR-T cell therapies, targeting gene insertion, non-viral DNA delivery, and cell therapy solutions with backing from Eli Lilly, Johnson & Johnson, and others.
-
-
Eli Lilly's Q1 2025 Financial report
Market Trend
Eli Lilly's Q1 2025 revenue surged 45% to $12.73B, driven by Mounjaro and Zepbound. U.S. GLP-1 prescription share hit 53.3%, surpassing Novo Nordisk. Key R&D and regulatory milestones achieved.
-
安顺市|
延津县|
乳山市|
瑞昌市|
兴国县|
永定县|
凤阳县|
泰州市|
东宁县|
隆德县|
罗田县|
平定县|
奇台县|
弋阳县|
古浪县|
永安市|
大埔区|
镇平县|
聂拉木县|
百色市|
玉田县|
邵阳县|
呼图壁县|
梓潼县|
成安县|
崇明县|
龙川县|
温宿县|
醴陵市|
江北区|
札达县|
新宾|
肥东县|
梁山县|
五华县|
遵义市|
玛纳斯县|
司法|
长海县|
信丰县|
长岛县|